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• To address this need, the Psoriasis Symptom Diary (PSD) was developed in accordance with recommendations set forth in the United States Food and Drug Administration's Guidance for Patient-Reported Outcome Measures.
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-The PSD was developed for use in global clinical trials, with the specific aim of generating patient-reported endpoints to test efficacy claims for treatments for moderate to severe chronic plaque psoriasis.
• The content validity of the PSD was evaluated through qualitative interviews and a review of the published literature. 4 Results indicated that the items measure signs, symptoms, and impacts of plaque psoriasis that are relevant and important to patients.
• Additional quantitative work, conducted using data from a phase 2 trial in patients with chronic plaque psoriasis, established sound initial estimates of item-level reliability, validity, and sensitivity to change and provided thresholds for responder definitions for use in the evaluation of treatment efficacy.
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SUMMARY AND CONCLUSIONS
• Using pooled phase 3 ERASURE and FIXTURE data, the analytic results indicate that the PSD severity items are reliable, demonstrate construct validity and discriminating ability, and are able to detect change.
• Analyses from the present phase 3 study confirm the positive psychometric evaluation conducted using the phase 2 secukinumab study data.
• The results support the use of these items to derive key secondary endpoints in future clinical trials and for use in clinical practice for the day-to-day management of psoriasis.
OBJECTIVE
• To confirm the psychometric properties (reliability, validity, responsiveness, and threshold for meaningful change) of the six PSD severity items using data from two phase 3 clinical trials of secukinumab in patients with moderate to severe chronic plaque-type psoriasis.
METHODS
• Data for this study came from pooling data from two randomized, double-blind, double-dummy, placebo-controlled, multicenter phase 3 trials, ERASURE (N = 737) and FIX-TURE (N = 1,305).
• The ERASURE and FIXTURE trials were designed to assess the efficacy and safety of subcutaneous secukinumab in patients with moderate to severe chronic plaque-type psoriasis.
• Both trials had four periods: screening (1 week to 4 weeks), induction (12 weeks), maintenance (40 weeks), and followup (8 weeks).
• Subjects in ERASURE were randomized 1:1:1 to receive 300 mg secukinumab, 150 mg secukinumab, or placebo.
• Subjects in FIXTURE were randomized 1:1:1:1 to receive 300 mg secukinumab, 150 mg secukinumab, 50 mg etanercept, or placebo.
• In both trials, subjects in the secukinumab arms received either two 150-mg injections or one 150-mg injection and one placebo injection, weekly for 4 weeks, followed by dosing every 4 weeks until week 48.
• In the FIXTURE trial, subjects randomized to etanercept received 50 mg subcutaneously twice weekly at baseline until week 12, then once weekly through week 51.
• The present study used 285 subjects from ERASURE and 535 subjects from FIXTURE for a total of 820 subjects who completed the PSD in the screening and induction (baseline and week 12) periods.
PSD Items
• The 16-item PSD consists of:
-Six severity items to evaluate signs and symptoms of plaque psoriasis (1, 3, 5, 7, 9, and 11)
-Seven items to evaluate patient-reported bother associated with the experience of those signs and symptoms (2, 4, 6, 8, 10, 12, and 14)
-One item to evaluate skin color (13) -Two items to evaluate psoriasis-related daily impacts (15 and 16)
• Patients are asked to evaluate their psoriasis-related symptoms and experiences over the past 24-hour reference period.
-Each item is assessed individually, yielding 16 scores ranging from 0 to 10, with higher scores indicating a worse condition.
-The diary is electronically administered each evening and is scheduled to be completed from screening through the induction period.
Other Measures
• Psoriasis Area and Severity Index (PASI)
• Investigator's Global Assessment modified 2011 (IGA mod 2011)
• Patient Global Impression of Change (PGIC)
• Dermatology Life Quality Index (DLQI)
• EuroQol 5-Dimension Health Status Questionnaire (EQ-5D) visual analog scale (VAS)
Psychometric Analyses
Test-Retest Reliability • Intraclass correlation coefficients (ICCs) were computed using data from screening week 1 as the "test" administration and data from screening week 2 as the "retest" administration.
Construct Validity
• Spearman correlation coefficients were computed between each PSD item and the PASI, IGA mod 2011, DQLI, and EQ-5D VAS scores at baseline and week 12.
• The PSD severity items were expected to be more strongly associated with the PASI and the DLQI scores than with the EQ-5D VAS score.
Known Groups Validity
• Analyses of variance examined mean differences in the PSD items by subgroup based on the PASI tertiles and the IGA mod 2011 (clear to mild [0 to 2]; moderate [3] ; severe [4] ).
Responsiveness
• Correlation of change scores in the PSD items with changes in the PASI, IGA mod 2011, and DQLI scores were computed.
Responder Thresholds
• The proportion of subjects with a change from baseline to week 12 at least as large as the phase 2-derived anchorbased thresholds was computed and tabulated by treatment group.
• Cumulative distribution function (CDF) plots were displayed graphically for the score change from baseline to week 12.
RESULTS
• Descriptive statistics indicated considerable improvement in symptoms between baseline and week 12 (Table 1 ).
• The PSD items yielded high test-retest reliability coefficients. ICCs were greater than 0.91, well above the recommended 0.70 threshold for multi-item tools.
• The patterns of correlations support the construct validity of the PSD items. Correlations between the PSD items and the PASI, IGA mod 2011, EQ-5D VAS, and DLQI total scores were in the anticipated direction, and by week 12 they were moderate to strong in magnitude (Table 1 ).
• In terms of discriminating ability, the PSD items differed predictably and significantly across known groups based on the PASI and IGA mod 2011.
• All PSD severity items demonstrated exceptional responsiveness based on the strong correlations observed between changes in the diary items and changes in the PASI, IGA mod 2011, and DLQI scores (Table 1 ).
• Using the phase 2-derived anchor-based PGIC thresholds to define meaningful change, the present study estimates that a larger proportion of subjects in the secukinumab treatment arms experienced meaningful change in key severity items than in the placebo arm (Table 2 ).
• CDF plots show that the percentage of responders was consistently higher in the secukinumab and etanercept (included in FIXTURE) treatment arms than in the placebo arm across the entire range of changes ( Figure 1 ). 
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